Why Bladder Cancer Comes Back After a Complete Resection

Last updated: August 30, 2026

• WordPress
• LinkedIn
• Mail

Many patients come to my clinic with painless blood in the urine and leave with a diagnosis of bladder cancer. After the tumour has been completely removed endoscopically, I always explain that regular cystoscopic checks will still be needed — and the question that follows is always the same: if you removed all of it, why do I need to keep coming back? This article answers that. It deals specifically with low-grade bladder cancer, meaning a tumour whose cells look relatively close to normal under the microscope, confirmed on the tissue diagnosis after surgery.

One clarification before we go on, because these two words are constantly mixed up. Grade describes how abnormal the cells look; stage describes how deeply the tumour has grown into the bladder wall. They are separate questions and your pathology report answers both. Low grade generally means a lower likelihood of the disease becoming life-threatening, but it does not mean no risk at all, and it is not the same thing as saying the tumour was superficial. Ask which grade and which stage yours was, and write both down — everything about your follow-up plan follows from those two answers.

Reason 1: the whole bladder lining has been exposed

The best-established risk factor for bladder cancer is smoking, which accounts for a large share of cases. The next is occupational exposure to certain industrial chemicals — the aromatic amines historically used in dye, rubber, leather, paint and some petroleum work. Others are recognised but less common: chronic bladder irritation or infection, previous pelvic radiotherapy, some chemotherapy drugs, and arsenic in drinking water. It is worth saying plainly that a good number of patients have none of these, so the absence of a risk factor never rules the diagnosis out, and having had one is not something to blame yourself for.

What these exposures share is the route by which they reach the bladder. Whether they are breathed in or absorbed through the skin, they enter the bloodstream, travel around the body, and are filtered out by the kidneys into the urine.

The urine then sits in the bladder — the storage organ — until the next time you pass water. That means the bladder lining has the longest contact time with those carcinogens of any organ in the urinary tract, repeated every day for decades. The consequence is that the exposure was never confined to the patch of lining where the tumour appeared: every cell of the bladder lining has had the same exposure, so any of them may become a tumour in the future. Removing all the visible tumour does not undo that history, which is why a new tumour can appear anywhere in the bladder later on.

Reason 2: tumour cell seeding

During endoscopic resection, tiny clusters of tumour cells are released and float in the bladder fluid, even after thorough irrigation. They behave like scattered seeds — drifting, settling on another part of the bladder lining, and growing there.

This one has a countermeasure. At the end of the operation the bladder can be filled with a chemotherapy solution that destroys those free-floating cells before they can implant, and for a low-risk tumour this single early instillation is recommended by guidelines and does measurably reduce recurrence (AUA/SUO guideline, 2024).

It is not given to everyone, though, and the reasons are good ones. It is deliberately withheld where the bladder wall may have been perforated during the resection, where the resection was unusually extensive, or where there is significant bleeding — in all three the drug could leak beyond the bladder and cause serious harm. It is also not given to anyone known to be allergic to the drug. So if you did not receive it, that is usually a considered decision rather than something overlooked, and it is a perfectly fair question to put to your surgeon.

What the recurrence figures actually are

Even with best practice, reported recurrence rates are 15–61% within 1 year of surgery and 31–78% within 5 years. Those ranges come from pooled trial data covering the whole spread of non-muscle-invasive tumours, from the mildest to the most aggressive, which is why they are so wide — and it is the reason the range on its own is close to useless for any individual. Your own risk is estimated from the specific features of your tumour: how many there were, how large, whether this was a first tumour or a recurrence, the grade, the stage, and whether carcinoma in situ was present. Urologists use published risk tables to turn those features into a number, and a patient at the favourable end of the scale sits nowhere near a patient at the unfavourable end. It is a reasonable thing to ask your own urologist for.

Read those numbers the right way. A recurrence is not a sign that the operation failed or that anything went wrong — it is an expected feature of this disease, and it is exactly what the surveillance programme exists to catch. Detected early, a recurrent tumour is usually straightforward to deal with. That is why keeping the cystoscopy appointments matters more than almost anything else you can do after the surgery.

What to report between appointments

Surveillance is a schedule, but it is not the only safety net. Contact your urology team, rather than waiting for the next appointment, if you notice:

• Blood in the urine, even a single episode, even if it is painless and settles on its own — this is how most bladder tumours announced themselves in the first place
• New urinary urgency, frequency or burning that does not settle, particularly if urine tests keep coming back clear — persistent irritative symptoms without infection can be the way carcinoma in situ presents
• Flank or pelvic pain, or unexplained weight loss

And some things need the same day rather than an appointment: being unable to pass urine, heavy bleeding with clots, or fever with rigors. Go to an emergency department — in Thailand you can call 1669.

The one thing that is in your own hands

If you smoke, stopping is the most useful thing you can do after the operation. I want to be accurate about why, because this is a place where well-meant advice is often overstated.

What is well established is that people who smoke have more recurrences and more progression than people who do not (Ślusarczyk et al., 2023). What is less settled is whether stopping after the diagnosis changes your own outcome. Several studies following patients over time suggest that those who quit do better (Rink et al., 2013). But the one study that checked smoking with a blood test rather than relying on what people reported found no difference in recurrence (Furberg et al., 2022), and a more recent study following patients forward concluded the picture remains unclear (Kiebach et al., 2025). So the honest summary is that a benefit is likely but has not been proven.

That uncertainty is not a reason to shrug, and guidelines do not treat it as one — stopping smoking is explicitly recommended as part of the initial care of anyone diagnosed with bladder cancer. The reasons stand up regardless of how the recurrence question is eventually settled: continued smoking keeps delivering carcinogens to a bladder lining that has already shown what it can do, it worsens outcomes if further surgery is ever needed, and it affects heart and lung health at exactly the point in life when those matter most. It is a hard thing to be told after a cancer diagnosis, and it is still worth saying. If you want help rather than instruction, ask — structured support works far better than willpower alone.

Frequently Asked Questions

Q1: If the surgeon removed all the tumour, why can bladder cancer still come back?

For two reasons. First, the carcinogens that caused the tumour reach the bladder in the urine and are held in contact with the entire bladder lining for years, so every cell of that lining shares the same risk — not only the area where the first tumour grew. Second, resection releases small clusters of tumour cells into the bladder fluid, which can settle elsewhere in the bladder and grow. Complete removal of the visible tumour addresses what can be seen, not the underlying exposure.

Q2: How often does bladder cancer recur?

Published pooled data report recurrence in 15–61% of patients within 1 year of resection, and 31–78% within 5 years. Those ranges span the whole spectrum of non-muscle-invasive disease, which is why they are so wide and why the range alone tells an individual patient very little. Your own estimate depends on the number and size of tumours, whether this was a first presentation or a recurrence, the grade and stage, and whether carcinoma in situ was present; urologists use published risk tables to work it out. A recurrence does not mean the original surgery was inadequate.

Q3: What is the difference between grade and stage?

Grade describes how abnormal the tumour cells look under the microscope; stage describes how deeply the tumour has grown into the bladder wall. They are separate and your pathology report gives both. Low grade generally carries a lower likelihood of the disease becoming life-threatening, but it is not the same as saying the tumour was superficial, and it does not mean surveillance can be relaxed. Ask for both your grade and your stage and keep a note of them, because the entire follow-up plan is built from those two answers.

Q4: Why do I need repeated cystoscopy after bladder tumour surgery?

Because recurrence is common and usually causes no symptoms at first. Flexible cystoscopy allows a recurrent tumour to be found while it is still small and superficial, when treatment is simpler and outcomes are better. Surveillance is not a sign that something went wrong — it is the standard of care for anyone who has had a bladder tumour removed.

Q5: Should I report new blood in the urine between cystoscopy appointments?

Yes. Anyone with a history of bladder tumour who notices blood in the urine should contact their urologist rather than waiting for the next scheduled appointment, even if the bleeding is painless and settles on its own. Painless bleeding was how most bladder tumours announced themselves in the first place. Persistent urgency, frequency or burning without an infection on testing is also worth reporting. Heavy bleeding with clots, an inability to pass urine, or fever with rigors needs same-day emergency assessment rather than a routine appointment.

Q6: Why was I not given chemotherapy into the bladder after my operation?

A single instillation of chemotherapy soon after resection is recommended for low-risk tumours and reduces recurrence, but it is deliberately withheld in several situations — where the bladder may have been perforated during resection, where the resection was extensive, or where there is significant bleeding, because the drug can then leak beyond the bladder and cause serious harm. It is also not given to anyone with a known allergy to the drug. Not receiving it is therefore often a considered decision rather than an omission, and it is a fair question to ask your surgeon.

Q7: Will stopping smoking reduce my risk of recurrence?

Probably, though it is fair to say the evidence is not as settled as you might expect. People who smoke clearly have more recurrences and more progression than people who do not. Whether quitting after diagnosis changes your own outcome is less certain: several follow-up studies suggest quitters do better, but a study that verified smoking with a blood test found no difference, and a recent prospective study concluded the question is still open. Guidelines nonetheless recommend stopping explicitly, and the reasons hold either way — continued smoking keeps delivering carcinogens to a bladder lining that has already produced one tumour, and it affects your outcome from any future surgery as well as your heart and lungs. Structured support works considerably better than willpower alone, so ask for it rather than trying to manage on your own.

Q8: Can I discuss bladder cancer follow-up by video consultation?

Yes, for reviewing results and planning. Bangkok Hospital Headquarters offers a Telemedicine service, arranged in advance by email to the Urology department at bhquro@bdms.co.th, and it is a practical way to go through a pathology report, understand your grade and stage, and agree a surveillance schedule — particularly for patients treated elsewhere or living abroad. Cystoscopy itself is a procedure and must be done in person. Samitivej Sriracha is in-person only, booked through the Urology department line 088-022-1445.

If you have a history of bladder cancer and need ongoing surveillance or flexible cystoscopy follow-up, Dr. Soarawee Weerasopone offers specialist consultations at Bangkok Hospital Headquarters. Book a Consultation. Appointments at Samitivej Sriracha Hospital can be arranged by calling the Urology department on 088-022-1445. Questions about the cost of surveillance or surgery should go to the hospital directly — for Bangkok Hospital, by email to bhquro@bdms.co.th.

References

• Sylvester RJ et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables. PubMed 16442208
• Holzbeierlein JM et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline, 2024 amendment. J Urol. 2024. doi:10.1097/JU.0000000000003846
• Ślusarczyk A et al. The impact of smoking on recurrence and progression of non-muscle invasive bladder cancer: systematic review and meta-analysis. J Cancer Res Clin Oncol. 2023. doi:10.1007/s00432-022-04464-6
• Rink M et al. Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. Eur Urol. 2013. doi:10.1016/j.eururo.2012.08.025
• Furberg H et al. Association of biochemically verified post-diagnosis smoking and non-muscle-invasive bladder cancer recurrence risk. J Urol. 2022. doi:10.1097/JU.0000000000002449
• Kiebach J et al. Smoking behaviour and the risks of tumour recurrence and progression in patients with non-muscle-invasive bladder cancer. Int J Cancer. 2025. doi:10.1002/ijc.35250

Disclaimer: This content is written and reviewed by Dr. Soarawee Weerasopone, a board-certified urologist at Bangkok Hospital Headquarters. It is intended for educational purposes only and does not constitute medical advice, and it cannot substitute for your own pathology report and the surveillance plan agreed with your own team. No medical advice, diagnosis or prescription is provided through personal messaging channels or social media. Always consult a qualified healthcare professional before starting any medical treatment. In an emergency, attend the nearest emergency department — in Thailand the emergency number is 1669.